InMed Pharmaceuticals Inc.
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $4.9M
- Net income
- -$8.2M
- Total assets
- $15.6M
- Market cap
- $5.2M
- Gross margin
- 34.5%
- Operating margin
- -95.3%
- Net margin
- -165.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $4.9M
- Cost of revenue
- $3.2M
- Gross profit
- $1.7M
- Operating expenses
- $9.7M
- Operating income
- -$4.7M
- Net income
- -$8.2M
- EPS (basic)
- $-8.36
- EPS (diluted)
- $-8.36
Balance sheet
- Total assets
- $15.6M
- Current assets
- $12.9M
- Total liabilities
- $2.1M
- Current liabilities
- $1.8M
- Shareholders’ equity
- $13.4M
Cash flow
- Operating cash flow
- -$7.8M
- Investing cash flow
- -$4.5M
- Financing cash flow
- $12.3M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
- Market cap
- $5.2M
- EPS (diluted)
- $-8.36
- Shares outstanding
- 3.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 10, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $8.2M in FY2025.
- Gross margin of 34.5%, net margin -165.1%.
- Trading 61% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review InMed Pharmaceuticals Inc..
Write a review
News about InMed Pharmaceuticals Inc.
News & sentiment via Polygon.io
